MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.
amyloid beta 42
drug development
pharmacodynamics
pharmacokinetics
preclinical
safety
tolerability
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
revised:
23
07
2024
received:
03
04
2024
accepted:
11
08
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
aheadofprint
Résumé
Small molecules and antibodies are being developed to lower amyloid beta (Aβ) peptides. We describe MEDI1814, a fully human high-affinity monoclonal antibody selective for Aβ MEDI1814 reduces free Aβ MEDI1814 offers a differentiated approach to impacting Aβ in AD via selective reduction of free Aβ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
World Health Organization. Dementia. 2022.
Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121:171‐181.
Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184‐185.
Hardy J. Testing times for the “amyloid cascade hypothesis”. Neurobiol Aging. 2002;23:1073‐1074.
Bogstedt A, Groves M, Tan K, Narwal R, McFarlane M, Hoglund K. Development of immunoassays for the quantitative assessment of amyloid‐beta in the presence of therapeutic antibody: application to pre‐clinical studies. J Alzheimers Dis. 2015;46:1091‐1101.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8:595‐608.
Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long‐term potentiation in vivo. Nature. 2002;416:535‐539.
Kayed R, Lasagna‐Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers Dis. 2013;33(1):S67‐S78. Suppl.
Cline EN, Bicca MA, Viola KL, Klein WL. The amyloid‐beta oligomer hypothesis: beginning of the third decade. J Alzheimers Dis. 2018;64:S567‐S610.
Panza F, Lozupone M, Watling M, Imbimbo BP. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease? Expert Rev Neurother. 2019;19:599‐602.
El‐Agnaf OM, Irvine GB. Review: formation and properties of amyloid‐like fibrils derived from alpha‐synuclein and related proteins. J Struct Biol. 2000;130:300‐309.
Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, et al. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627‐633.
Kuperstein I, Broersen K, Benilova I, et al. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010;29:3408‐3420.
Saito T, Suemoto T, Brouwers N, et al. Potent amyloidogenicity and pathogenicity of Abeta43. Nat Neurosci. 2011;14:1023‐1032.
Jawhar S, Wirths O, Schilling S, Graubner S, Demuth HU, Bayer TA. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock‐out rescues the behavioral phenotype in 5XFAD mice. J Biol Chem. 2011;286:4454‐4460.
Perez‐Garmendia R, Gevorkian G. Pyroglutamate‐modified amyloid beta peptides: emerging targets for Alzheimer s disease immunotherapy. Curr Neuropharmacol. 2013;11:491‐498.
Meissner JN, Bouter Y, Bayer TA. Neuron loss and behavioral deficits in the TBA42 mouse model expressing N‐truncated pyroglutamate amyloid‐beta3‐42. J Alzheimers Dis. 2015;45:471‐482.
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691‐1704.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2022;388:9‐21.
Budd Haeberlein S, O'Gorman J, Chiao P, et al. Clinical development of aducanumab, an anti‐aβ human monoclonal antibody being investigated for the treatment of early Alzheimer's disease. J Prev Alzheimers Dis. 2017;4:255‐263.
US Food & Drug Administration. Drug Approval Package: Aduhelm (aducanumab‐avwa). 2021.
US Food & Drug Administration. Drugs@FDA: FDA‐Approved Drugs—Lecanemab irmb. 2023.
Willis BA, Sundell K, Lachno DR, et al. Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia. Alzheimers Dement (N Y). 2018;4:652‐660.
Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016;12:110‐120.
Plotkin SS, Cashman NR. Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Neurobiol Dis. 2020;144:105010.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263‐269.
Daramola O, Stevenson J, Dean G, et al. A high‐yielding CHO transient system: coexpression of genes encoding EBNA‐1 and GS enhances transient protein expression. Biotechnol Prog. 2014;30:132‐141.
Hoet RM, Cohen EH, Kent RB, et al. Generation of high‐affinity human antibodies by combining donor‐derived and synthetic complementarity‐determining‐region diversity. Nat Biotechnol. 2005;23:344‐348.
Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992;226:889‐896.
Vaughan TJ, Williams AJ, Pritchard K, et al. Human antibodies with sub‐nanomolar affinities isolated from a large non‐immunized phage display library. Nat Biotechnol. 1996;14:309‐314.
Clarkson T, Lowman HB. Phage Display: A Practical Approach. Oxford University Press, 2004; 2004.
Lewis L, Lloyd C. Optimisation of antibody affinity by ribosome display using error‐prone or site‐directed mutagenesis. Methods Mol Biol (Clifton, NJ). 2012;805:139‐161.
Karlsson R, Michaelsson A, Mattsson L. Kinetic analysis of monoclonal antibody‐antigen interactions with a new biosensor based analytical system. J Immunol Methods. 1991;145:229‐240.
Ashton NJ, Puig‐Pijoan A, Mila‐Aloma M, et al. Plasma and CSF biomarkers in a memory clinic: head‐to‐head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2023;19:1913‐1924.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280‐292.
Groves MA, Nickson AA. Affinity maturation of phage display antibody populations using ribosome display. Methods Mol Biol (Clifton, NJ). 2012;805:163‐190.
Oganesyan V, Damschroder MM, Leach W, Wu H, Dall'Acqua WF. Structural characterization of a mutated, ADCC‐enhanced human Fc fragment. Mol Immunol. 2008;45:1872‐1882.
Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11:812.
Sgourakis NG, Yan Y, McCallum SA, Wang C, Garcia AE. The Alzheimer's peptides Abeta40 and 42 adopt distinct conformations in water: a combined MD /NMR study. J Mol Biol. 2007;368:1448‐1457.
Schilling LP, Pascoal TA, Zimmer ER, et al. Regional amyloid‐beta load and white matter abnormalities contribute to hypometabolism in Alzheimer's dementia. Mol Neurobiol. 2019;56:4916‐4924.
Schlenzig D, Manhart S, Cinar Y, et al. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry. 2009;48:7072‐7078.
Patterson BW, Elbert DL, Mawuenyega KG, et al. Age and amyloid effects on human central nervous system amyloid‐beta kinetics. Ann Neurol. 2015;78:439‐453.
Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012;8:261‐271.
Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med. 2021;27:1187‐1196.